BNTX vs NEO: fair value comparison
BioNTech SE and NeoGenomics, Inc. · Updated 2026-10-19
BNTX reports in EUR, so no same-currency fair-value verdict is published for it. NEO's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, BNTX currently ranks higher by quality score.
| BNTX | NEO | |
|---|---|---|
| Verdict | Awaiting full valuation | Awaiting full valuation |
| Last price | $96.85 | $16.65 |
| 12-month range | $83.89–$119.34 | $7.19–$19.91 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #127 of 301 Healthcare | #128 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | Declining | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: BNTX fair value analysis · NEO fair value analysis